Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
Phathom Pharmaceuticals filed a Form 8-K dated May 5, 2020, reporting entry into a material definitive agreement. The company is developing vonoprazan products under an exclusive license from Takeda Pharmaceutical Company Limited for specified formulations and human therapeutic uses in the United States, Europe, and Canada.
Material agreement and key terms
- On May 5, 2020, Phathom entered into a Commercial Supply Agreement with Takeda.
- Takeda will supply, and Phathom will purchase, commercial quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch.
- The agreement establishes annual minimum and maximum batch quantities. If Phathom fails to purchase the annual minimum, other than because of Takeda’s supply inability or force majeure, Phathom must pay for the missing batches.
- Takeda is not obligated to supply quantities above the annual maximum. After July 15, 2020, additional batches may be agreed in writing if Takeda has capacity.
- Takeda will provide materials and support for technology transfer and manufacturing know-how to Phathom’s contract manufacturers. Phathom will pay related technology-transfer costs and services.
- The agreement generally runs for two years from the first commercial-launch order in the territory, but no later than December 31, 2023. Beginning January 1, 2021, the parties will negotiate in good faith regarding a longer-term supply agreement.
- The agreement may be terminated for an uncured material breach and terminates immediately if the related Takeda license agreement terminates.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, purchase commitments in dollar terms, or other financial metrics. The fixed per-batch price and specific minimum and maximum batch quantities are not disclosed in the filing text.
Guidance, outlook, risks, and unusual items
- The agreement supports potential commercialization of vonoprazan but does not provide a launch date, sales guidance, or financial outlook.
- Phathom faces minimum-purchase obligations and potential payments for batches not purchased, subject to stated exceptions.
- Supply above the contractual maximum is not assured, creating potential capacity constraints if demand exceeds planned quantities.
- Technology transfer to contract manufacturers will require additional costs and services.
- The supply arrangement depends on the continued effectiveness of the Takeda license agreement and may be terminated for an uncured material breach.
- The complete Commercial Supply Agreement will be filed as an exhibit to Phathom’s Form 10-Q for the quarter ending June 30, 2020.
Key facts for investors to verify
- Exact fixed price per batch and annual minimum and maximum batch commitments.
- Potential dollar exposure from minimum-purchase obligations and technology-transfer costs.
- Timing and status of vonoprazan commercialization and initial commercial-launch orders.
- Terms of the related Takeda License Agreement and any termination or renewal provisions.
- Additional terms in the complete supply agreement, including delivery, quality, indemnification, and termination provisions.